|
1.
|
Das PM and Singal R: DNA methylation and
cancer. J Clin Oncol. 22:4632–4642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Esteller M, Corn PG, Baylin SB and Herman
JG: A gene hyper-methylation profile of human cancer. Cancer Res.
61:3225–3229. 2001.PubMed/NCBI
|
|
3.
|
van Engeland M, Roemen GM, Brink M, et al:
K-ras mutations and RASSF1A promoter methylation in colorectal
cancer. Oncogene. 21:3792–3795. 2002.
|
|
4.
|
Preuss I, Eberhagen I, Haas S, Eibl RH,
Kaufmann M, von Minckwitz G and Kaina B:
O6-methylguanine-DNA methyltransferase activity in
breast and brain tumors. Int J Cancer. 61:321–326. 1995.
|
|
5.
|
Newcomb EW, Alonso M, Sung T and Miller
DC: Incidence of p14ARF gene deletion in high-grade
adult and pediatric astrocytomas. Hum Pathol. 31:115–119. 2000.
|
|
6.
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Song MS, Song SJ, Ayad NG, et al: The
tumor suppressor RASSF1A regulates mitosis by inhibiting the
APC-Cdc20 complex. Nat Cell Biol. 6:129–137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Rubinfeld B, Souza B, Albert I, et al:
Association of the APC gene product with beta-catenin. Science.
262:1731–1734. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Su LK, Vogelstein B and Kinzler KW:
Association of the APC tumor suppressor protein with catenins.
Science. 262:1734–1737. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
van den Donk M, Pellis L, Crott JW, et al:
Folic acid and vitamin B-12 supplementation does not favorably
influence uracil incorporation and promoter methylation in rectal
mucosa DNA of subjects with previous colorectal adenomas. J Nutr.
137:2114–2120. 2007.
|
|
11.
|
van Engeland M, Weijenberg MP, Roemen GM,
et al: Effects of dietary folate and alcohol intake on promoter
methylation in sporadic colorectal cancer: the Netherlands cohort
study on diet and cancer. Cancer Res. 63:3133–3137. 2003.PubMed/NCBI
|
|
12.
|
van den Bent MJ, Dubbink HJ, Sanson M, et
al: MGMT promoter methylation is prognostic but not predictive for
outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial
tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin
Oncol. 27:5881–5886. 2009.PubMed/NCBI
|
|
13.
|
Löf-Öhlin ZM and Nilsson TK:
Pyrosequencing assays to study promoter CpG site methylation of the
O6-MGMT, hMLH1, p14ARF,
p16INK4a, RASSF1A and APC1A genes. Oncol
Rep. 21:721–729. 2009.PubMed/NCBI
|
|
14.
|
Aoyagi H, Iida S, Uetake H, et al: Effect
of classification based on combination of mutation and methylation
in colorectal cancer prognosis. Oncol Rep. 25:789–794.
2011.PubMed/NCBI
|
|
15.
|
Esteller M, Tortola S, Toyota M, Capella
G, Peinado MA, Baylin SB and Herman JG: Hypermethylation-associated
inactivation of p14(ARF) is independent of p16(INK4a) methylation
and p53 mutational status. Cancer Res. 60:129–133. 2000.PubMed/NCBI
|
|
16.
|
Kamiyama H, Noda H, Takata O, Suzuki K,
Kawamura Y and Konishi F: Promoter hypermethylation of
tumor-related genes in peritoneal lavage and the prognosis of
patients with colorectal cancer. J Surg Oncol. 100:69–74. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Chen SP, Chiu SC, Wu CC, et al: The
association of methylation in the promoter of APC and MGMT and the
prognosis of Taiwanese CRC patients. Genet Test Mol Biomarkers.
13:67–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Noda H, Mashima R, Kamiyama H, Okada S,
Kawamura YJ and Konishi F: Promoter hypermethylation of
tumor-related genes in sporadic colorectal cancer in young
patients. J Exp Clin Cancer Res. 26:521–526. 2007.PubMed/NCBI
|
|
19.
|
Krtolica K, Krajnovic M, Usaj-Knezevic S,
Babic D, Jovanovic D and Dimitrijevic B: Comethylation of p16 and
MGMT genes in colorectal carcinoma: correlation with
clinicopathological features and prognostic value. World J
Gastroenterol. 13:1187–1194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kohonen-Corish MR, Daniel JJ, Chan C, et
al: Low microsatellite instability is associated with poor
prognosis in stage C colon cancer. J Clin Oncol. 23:2318–2324.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Nakayama G, Hibi K, Kodera Y, Koike M,
Fujiwara M and Nakao A: P16 methylation in serum as a potential
marker for the malignancy of colorectal carcinoma. Anticancer Res.
27:3367–3370. 2007.PubMed/NCBI
|
|
22.
|
Lee M, Han WS, Kim OK, Sung SH, Cho MS,
Lee SN and Koo H: Prognostic value of p16INK4a and
p14ARF gene hypermethylation in human colon cancer.
Pathol Res Pract. 202:415–424. 2006.
|
|
23.
|
Sanz-Casla MT, Maestro ML, Vidaurreta M,
Maestro C, Arroyo M and Cerdan J: p16 Gene methylation in
colorectal tumors: correlation with clinicopathological features
and prognostic value. Dig Dis. 23:151–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Zou HZ, Yu BM, Wang ZW, et al: Detection
of aberrant p16 methylation in the serum of colorectal cancer
patients. Clin Cancer Res. 8:188–191. 2002.
|
|
25.
|
Dominguez G, Silva J, Garcia JM, et al:
Prevalence of aberrant methylation of p14ARF over
p16INK4a in some human primary tumors. Mutat Res.
530:9–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Olschwang S, Hamelin R, Laurent-Puig P, et
al: Alternative genetic pathways in colorectal carcinogenesis. Proc
Natl Acad Sci USA. 94:12122–12127. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Shen L, Catalano PJ, Benson AB III,
O’Dwyer P, Hamilton SR and Issa JP: Association between DNA
methylation and shortened survival in patients with advanced
colorectal cancer treated with 5-fluorouracil based chemotherapy.
Clin Cancer Res. 13:6093–6098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hoffmann AC, Vallböhmer D, Prenzel K, et
al: Methylated DAPK and APC promoter DNA detection in peripheral
blood is a significantly associated with apparent residual tumor
and outcome. J Cancer Res Clin Oncol. 135:1231–1237. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Kim JC, Choi JS, Roh SA, Cho DH, Kim TW
and Kim YS: Promoter methylation of specific genes is associated
with the phenotype and progression of colorectal adenocarcinomas.
Ann Surg Oncol. 17:1767–1776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Wettergren Y, Odin E, Nilsson S, Carlsson
G and Gustavsson B: p16INK4a gene promoter
hypermethylation in mucosa as a prognostic factor for patients with
colorectal cancer. Mol Med. 14:412–421. 2008. View Article : Google Scholar
|
|
31.
|
Tommasi S, Pinto R, Petriella D, et al:
Oncosuppressor methylation: a possible key role in colon metastatic
progression. J Cell Physiol. 226:1934–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Weller M, Felsberg J, Hartmann C, et al:
Molecular predictors of progression-free and overall survival in
patients with newly diagnosed glioblastoma: a prospective
translational study of the German Glioma Network. J Clin Oncol.
27:5743–5750. 2009. View Article : Google Scholar
|
|
33.
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Esteller M, Garcia-Foncillas J, Andion E,
et al: Inactivation of the DNA-repair gene MGMT and the clinical
response of gliomas to alkylating agents. N Engl J Med.
343:1350–1354. 2000. View Article : Google Scholar
|
|
35.
|
Jaeckle KA, Eyre HJ, Townsend JJ, et al:
Correlation of tumor O6 methylguanine-DNA
methyltransferase levels with survival of malignant astrocytoma
patients treated with bis-chloroethylnitrosourea: a Southwest
Oncology Group study. J Clin Oncol. 16:3310–3315. 1998.
|
|
36.
|
Hegi ME, Diserens AC, Godard S, et al:
Clinical trial substantiates the predictive value of
O-6-methylguanine-DNA methyltransferase promoter methylation in
glioblastoma patients treated with temozolomide. Clin Cancer Res.
10:1871–1874. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Stupp R and Hegi ME: Methylguanine
methyltransferase testing in glioblastoma: when and how? J Clin
Oncol. 25:1459–1460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Shima K, Morikawa T, Baba Y, et al: MGMT
promoter methylation, loss of expression and prognosis in 855
colorectal cancers. Cancer Causes Control. 22:301–309. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Löf-Öhlin ZM, Sorbe B, Wingren S and
Nilsson TK: Hypermethylation of promoter regions of the
APC1A and p16INK4a genes in relation to
prognosis and tumor characteristics in cervical cancer patients.
Int J Oncol. 39:683–688. 2011.
|
|
40.
|
Carmona FJ and Esteller M: Moving closer
to a prognostic DNA methylation signature in colon cancer. Clin
Cancer Res. 17:1215–1217. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Yi JM, Dhir M, Van Neste L, et al: Genomic
and epigenomic integration identifies a prognostic signature in
colon cancer. Clin Cancer Res. 17:1535–1545. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Cui T, Chen Y, Yang L, Knösel T, Zöller K,
Huber O and Petersen I: DSC3 expression is regulated by p53, and
methylation of DSC3 DNA is a prognostic marker in human colorectal
cancer. Br J Cancer. 104:1013–1019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Tong JD, Jiao NL, Wang YX, Zhang YW and
Han F: Downregulation of fibulin-3 gene by promoter methylation in
colorectal cancer predicts adverse prognosis. Neoplasma.
58:441–448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
van Engeland M, Derks S, Smits KM, Meijer
GA and Herman JG: Colorectal cancer epigenetics: complex
simplicity. J Clin Oncol. 29:1382–1391. 2011.PubMed/NCBI
|
|
45.
|
Jover R, Nguyen TP, Pérez-Carbonell L, et
al: 5-Fluorouracil adjuvant chemotherapy does not increase survival
in patients with CpG island methylator phenotype colorectal cancer.
Gastroenterology. 140:1174–1181. 2011. View Article : Google Scholar : PubMed/NCBI
|
